Seneca Biopharma and Jiangsu QYuns Therapeutics Announce Development Plan for Potential Joint Pipeline at 7th China Renaissance Healthcare and Life Science Leadership Summit

Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA

Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases

Neuralstem Becomes Seneca Biopharma

Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4)

Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

Neuralstem Reports Second Quarter 2019 Fiscal Results

Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing

Neuralstem Closes $7.5 Million Underwritten Public Offering

Neuralstem Announces Pricing of $7.5 Million Underwritten Public Offering